An experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drug’s maker, Pfizer.
Stopping a clinical trial is a rare action that’s typically taken when a therapy appears to be very effective or clearly dangerous. In both those cases, it’s considered unethical to continue a
In a randomized clinical trial that included more than 1,900 patients who tested positive for COVID-19 and were at risk for having severe complications for their infections, those who received Paxlovid within 3 days of the start of their symptoms were 89% less likely to be hospitalized than those who got a placebo pill -- three patients out of 389 who got the drug were hospitalized, compared with 27 out of 385 who got the placebo.
The U.K. became the first country to authorize the use of molnupiravir, which is brand-named Lagevrio. "They both demonstrate that, with appropriate investment, the development of bespoke direct-acting antiviral drugs targeting SARS-CoV2 was eminently feasible and has ultimately proven far more successful than repurposing other drugs with questionable antiviral effects," said Griffin, who was not involved in the development of either drug.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Pfizer says its experimental pill reduces risk of hospitalization, death from Covid-19Drugmaker Pfizer said Friday its experimental pill designed to fight coronavirus reduced the risk of hospitalization and death for high-risk patients taking part in a trial of the drug.
Les mer »
Pfizer COVID-19 vaccine now available for kids ages 5 to 11: 5 things to knowAn 8-year-old receives his vaccine—and gets a hug from Dr. Bear—at a Washington hospital. What to know as the Pfizer COVID-19 vaccine is now available for kids ages 5 to 11:
Les mer »
COVID-19 live updates: Don't give kids pain reliever before vaccine, CDC saysAs the COVID-19 pandemic has swept the globe, more than 5 million people have died from the disease worldwide, including over 749,000 Americans.
Les mer »
Air Force says nearly 8,500 miss deadline for COVID-19 shotsWASHINGTON (AP) — Nearly 8,500 active duty members of the Air Force and Space Force have missed the deadline for getting COVID-19 vaccinations, including 800 who flatly refused and nearly 5,000 with pending requests for a religious exemption, the Air Force said Wednesday.
Les mer »
Air Force says nearly 97% of active members complied with COVID-19 vaccine mandateThe Air Force said Wednesday that nearly 97% of its approximately 326,000 active duty service members have complied with Secretary of Defense Lloyd Austin's mandate and have received at least one dose of a coronavirus vaccine before the branch's Nov. 2 deadline.Why it matters: Around 8,500 active members missed the deadline. Many of them have filed for medical exemptions and religious accommodations, which are being reviewed by the department.Get market news worthy of your time with Axios Market
Les mer »